KRX Bio Technology Transfer Index

Announced that partner company SOTIO Biotech received Orphan Drug Designation (ODD) from the U.S. FDA for SOT106, an ADC for osteosarcoma treatment that utilizes LigaChem's 'ConjuAll' platform technology. This validation of the platform is estimated to have a medium market impact, expected.

The company's natural new drug for gastritis, 'Zitec', is scheduled to receive conditional reimbursement approval from the Health Insurance Review and Assessment Service's (HIRA) drug evaluation committee on June 4, 2026, provided the company accepts a price below the evaluated amount. Estimated price impact >=5% as this is a critical step for market entry scheduled.

ABL Bio submitted an amended Investigational New Drug (IND) application to Korea's MFDS for its immuno-oncology candidate ABL503 on 2026-06-04. The amendment expands the ongoing Phase 1 trial to include a new monotherapy cohort and a new combination therapy arm with a PD-1 inhibitor.

Eli Lilly exercised an option to expand its collaboration with competitor Camurus for a long-acting drug delivery technology on June 1, 2026, increasing competition for Peptron's SmartDepot platform; estimated >10% price impact expected.

Announced a partnership with Chime Biologics for the development and commercialization of a biosimilar for the immunology drug 'Dupixent', a blockbuster drug with estimated global sales of KRW 27 trillion.

Hanmi Pharm announced a licensing and collaboration agreement with Eli Lilly for its GLP-2 agonist 'Sonefpeglutide' for up to $1.26 billion on June 1, 2026, including a $75 million upfront payment.

Voronoi presented positive clinical trial data for VRN11 at ASCO 2026 on June 1, 2026. High importance is estimated due to strong anti-tumor response in brain metastases, a major unmet need, scheduled.

Presentation of updated long-term data from the CHRYSALIS-2 study for Rybrevant and Lazcluze combination at ASCO 2026, with an estimated 5-10% price impact due to positive clinical results, scheduled.

Receipt of a $30 million milestone payment from Janssen Biotech for European commercialization of Lazertinib, with an estimated 5-10% price impact due to significant cash inflow, expected.

The abstract for Peptron's long-acting obesity treatment candidate PT403 was released ahead of its presentation at the ADA 2026 conference, including pilot results from healthy adults; estimated >5% price impact scheduled.

Receipt of IND approval from the Korean Ministry of Food and Drug Safety for Phase 1 clinical trial of YH25724, with an estimated 1-5% price impact as an early-stage milestone, expected.